Evidence-based conservative therapy of gastroesophageal reflux disease;Evidenzbasierte konservative therapie der gastroösophagealen refluxkrankheit

Internist

Volumn 44, Issue 1, 2003, Pages 21-27

  Schilling, D ^b   Riemann, J F ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; DOMPERIDONE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

BARRETT ESOPHAGUS; CONSERVATIVE TREATMENT; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; LIFESTYLE; REMISSION; REVIEW; TREATMENT OUTCOME;

EID: 0037280003     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-002-0786-3     Document Type: Review

References (49)

1. Allen ML, Mellow MH, Robinson MG (1990) The effect of raw onion on acid reflux and reflux symptoms. Am J Gastoenterol 85: 377-380
2. Andersson T (1996) Pharmacokinetics, metabolism and interaction of acid pump inhibitors. Focus on omeprazole lansoprazole and pantoprazole. Clin Pharmacokinet 31: 9-28
3. Avidan B, Sonneberg A, Schnell TG, Sontag SJ (2002) Walking and chewing reduce postprandial acid reflux. Aliment Pharmacol Ther 15: 151-155
4. Barbezat GO, Schlup M, Lubcke R (1999) Omeprazole therapy decresees the need for dilatation of peptic oesophageal strictures. Aliment Pharmacol Ther 13: 1041-1045
5. Chiba N, De Gara CHJ, Wikinson JM, Hunt RH (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 112: 1798-1810
6. Dent J, Brun J, Fendrick, Fennerty MB et al. on behalf of the Genval Workshop Group (1999) An evidence-based appraisal of reflux disease management - The Genval Workshop Report. Gut 44 (Suppl 2)
7. Edwards J, Lind T, Lundell L (2001) Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 15: 1729-1736
8. Festen HPM, Schenk E, Tan G, Snel P, Nelis F (1999) Omeprazole versus high dose Ranitidine in mild gastroesophageal reflux disease: Short and long term treatment. Am J Gastoenterol 94: 931-936
9. Fitzgerald RC, Lascar R, Triadafilopoulos G (2001) Barrett's oesophagus, dysplasia and pharmacological acid suppression. Aliment Pharmacol Ther 15: 269-276
10. Gesron LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G (2000) A cost effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 95: 395-407
11. Harvey RF, Gordon PC, Hadley N et al. (1987) Effects of sleeping with bed head rised and ranitidine in patients with severe peptic esophagitis. Lancet 2: 1200-1203
12. Heading RC, Baldi F, Holloway RH et al. (1998) Prokinetics in the treatment of gastroesophageal reflux disese. Eur J Gastroenterol 10: 87-93
13. Holtmann Gcain CR, Malfertheiner P (1999) Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 117: 11-16
14. Humphries TJ, Merritt GJ (1999) Review article: drug interactions with agents used to treat acid related diseases. Aliment Pharmacol Ther 13: 18-26
15. Inadomi JM, Jamal R, Murata GH (2001) Step down management of gastroesophageal reflux disease. Gastroenterology 121: 1095-1100
16. Iskedjian M, Einarson TR (1998) Meta analyses of cisapride, omeprazole and ranitidine in the treatment of GORD. Implications for treating patient subgroups. Clin Drug Invest 16: 9-18
17. Kahrilas PJ (1992) Cigarette smoking and gastroesophageal reflux disease. Dig Dis Sci 10: 61-71
18. Kahrilas PJ, Falk GW, Johnson DA et al. (2000) Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: A randomised controlled trial. Aliment Pharmacol Ther 14: 1249-1248
19. Kjellin A, Ramel S, Rössner S, Thor K (1996) Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J gastroenterol 31: 1047-1051
20. Klinkenberg-Knol EC, Festen HP, Jansen JB et al. (1994) Long-term treatment with Omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 121: 161-167
21. Klinkenberg-Knol EC, Nelis F, Dent J et al. Long Term Study Group (2000) Long term Omeprazole in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 118: 661-669
22. Labenz J, Malfertheiner P (1997) Helicobacter pylori in gastroesophageal reflux disease: causal agent, independent or protective factor? Gut 41: 277-280
23. Labenz J, Petersen KU, Rösch W, Koelz R (2002) Auswahl von Protonenpumpen-Inhibitoren. Dtsch Ärztebl 99: B 2069-2073
24. Lagergren J, Bergström R, Nyren O (2000) No relation between body mass and gastro-oesophageal reflux symptoms in a swedish population based study. Gut 47: 26-29
25. Lind T, Havelund T Lundell L (1999) On demand therapy with omeprazole for the longterm management of patients with heartburn without esophagitis - a placebo controlled randomized trial. Aliment Pharmacol Ther 13: 907-914
26. Lundell L, Miettinen P, Myrvold HE et al. and the Nordic GORD Study Group (2000) Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. Eur J Gastroenterol Hepatol 12: 879-887
27. Madisch A, Hotz J, Londong W, Arnold R, Gugler R, Hermanns ML, Layer P (2002) Erosive Refluxkrankheit (ERD) konservative Therapie. Konsensuskonferenz Leitlinien der DGVS Gastroösophageale Refluxkrankheit (in Vorbereitung)
28. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT (2001) Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 121: 1120-1126
29. Murphy DW, Castell DO (1988) Chocolate and heartburn: evidence of increased esophageal acid exposure after chocolate ingestion. Am J Gastroenterol 83: 663-666
30. Myrvold HE, Lundell L, Miettinen P et al. and the Nordic GORD Study group (2001) The cost of long-term therapy for gastroesophageal reflux disease: a randomized trial comparing omeprazole and open antireflux surgery. Gut 49: 488-494
31. O'Connor HJ (1999) Helicobacter pylori and gastroesophageal reflux disease - clinical implications and management. Aliment Pharmacol Ther 13: 117-127
32. Ofman JJ, Dorn GH, Fennerty MB, Fass R (2002) The clinical and economic impact of competing management strategies for gastroesophageal reflux disease. Aliment Pharmacol Ther 16: 261-273
33. Pehl C, Pfeiffer A, Wendl B, Kaess H (1997) Effect of decaffeination of coffee on gastroesophageal reflux in patients with reflux disease. Aliment Pharmacol Ther 11: 483-486
34. Pehl C, Waizenhofer A, Wendl B, Schmidt T, Schepp W, Pfeiffer A (1999) Effect of low and high fat meals on lower esophageal sphincter motility and gastroesophageal reflux in healthy subjects. Am J Gastroenterol 94 1192-1196
35. Penagini R, Carmagnola S, Cantu P (2002) Review article: gastro-oesophageal reflux disease - pathophysiological issues on clinical relevance. Aliment Pharmacol Ther 16 (Suppl 4): 65-71
36. Quatu-Lascar R, Fitzgerald RC, Triadafilopoulos G (1999) Differentiation and proliferation in Barrett's esophagus and the effect of acid suppression. Gastroenterology 117: 327
37. Revicki DA, Wood M, Maton PN, Sorensen S (1998) The impact of gastroesophageal reflux disease on health related quality of life. Am J Med 104: 252-258
38. Richter JE, Kahrilas PJ, Johanson J et al. for the Esomeprazole Study investigators (2001) Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomised controlled trial. Am J Gastroenterol 96: 565-665
39. Sabesin SM, Berlin RG, Humphries TJ, Bradstreet DC, Walton-Bowen KL, Zaidi S (1994) Famotidine relieves symptoms of gastroesophageal reflux diseaes and heals erosions and ulcerations results of a multicenter, placebo-controlled, dose-ranging study. Arch Intern Med 151: 2394-23400
40. Sachs G (1997) Proton pump inibitors and acid-related diseases. Pharmacotherapy 17: 22-37
41. Schwizer W, Thumshirn M, Dent J, Guldenschuh I, Menne D, Cathomas G, Fried M (2001) Helicobacter pylori and symptomatic relapse on gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 357: 1738-1742
42. Shirvani VN, Quatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G (2000) Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 118: 487-496
43. Talley Lauritsen K, Tunturi AR, Hihnala H (2001) Esomeprazole 20 mg maintains symptom control in endoscopy negative gastro-esophageal reflux disease. A controlled trial of on demand therapy for 6 months. Aliment Pharmacol Ther 15: 347-354
44. Van Pinxteren B, Numans ME, Bonis PA, Lau J (2002) Short term treatment with proton pump inhibitors, H2 receptor antagonists and prokinetics fpor gastroesophageal reflux disease- like symptoms and endoscopy negative reflux disease (cochrane Review). Cochrane Library 2
45. Van Rensburg CJ, Honiball PJ et al. (1999) Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux esophagitis - a 2 year follow up. Aliment Pharmacol Ther 13: 1023-1028
46. Vigneri S, Termini R, Leandro G et al. (1995) A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333: 1106-1110
47. Wilson LJ, Ma W, Hirschowitz BI (1999) Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol 94: 2840-2844
48. 2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 116: 239-247
49. B agonists baclofen in patients with gastroesophageal reflux disease. Gut 50: 19-24